AstraZeneca: positive results for cancer drug Imfinzi
(CercleFinance.com) - AstraZeneca announced on Wednesday that its immunotherapy Imfinzi has shown positive results in phase III clinical trials in patients with liver cancer.
Combined with tremelimumab, another anti-cancer drug, the monoclonal antibody demonstrated an "unprecedented" survival rate in the first-line treatment of non-operable liver cancer, with 31% of patients alive after three years.
The study also showed that a dose of tremelimumab and Imfinzi given every four weeks reduced the risk of death by 22%.
More than half of patients with inoperable liver cancer are diagnosed in the advanced stages of their disease, reducing the number of treatment options available to them.
AstraZeneca also announced on Wednesday that Imfinzi improved survival in patients with biliary tract cancer in another phase III study.
Copyright (c) 2022 CercleFinance.com. All rights reserved.